Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Incidence and Risk Factors for Post-Intravitreal Injection Endophthalmitis in a Modified Operating Room Setting Publisher Pubmed



Zarei M1 ; Karkhaneh R1 ; Mahmoudzadeh R1 ; Salabati M1 ; Nabavi A1 ; Yaseri M2 ; Najibzadeh E1 ; Roohipoor R1 ; Riazi Esfahani M1 ; Khodabande A1 ; Ghassemi F1 ; Ebrahimiadib N1 ; Khojasteh H1 ; Modjtahedi BS3, 4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Department of Ophthalmology, Southern California Permanente Medical Group, Baldwin Park, CA, United States
  4. 4. Eye Monitoring Center, Kaiser Permanente Southern California, Baldwin Park, CA, United States

Source: Ocular Immunology and Inflammation Published:2019


Abstract

Purpose: To evaluate the incidence and risk factors of post-intravitreal injection (IVI) endophthalmitis in a single center modified operating room (OR) setting. Methods: In a retrospective chart review study, patients who underwent IVI in a modified OR between September 2014 and November 2016 were included. Cases of post-IVI endophthalmitis were identified from the Hospital Infection Control Committee records, which tracks all post-procedure infections. Results: 51 472 IVIs (37 814 patients) including 13 658 bilateral simultaneous injections were performed during the study period. There were 17 cases of endophthalmitis (0.033%, 95% CI 0.019%-0.052%). There were no cases of bilateral endophthalmitis. Age, sex, indication for IVI, simultaneous bilateral injections, number of previous injections, and type of injected drug were not significantly associated with incidence of endophthalmitis. Conclusion: Post-IVI endophthalmitis is rare in this modified OR setting. Simultaneous bilateral IVIs and on-site preparation of injections are safe under these conditions. © 2019, © 2019 Taylor & Francis Group, LLC.